Il punto su
Disturbi dello spettro autistico: fenotipi, genotipi, marcatori e prospettive terapeutiche
AUTISTIC SPECTRUM DISORDERS: PHENOTYPES, GENOTYPES, MARKERS AND THERAPEUTIC PERSPECTIVES
Marina Marini
Dipartimento di Medicina e Chirurgia (DIMEC), sezione di Istologia, Embriologia e Biologia Applicata, Università di Bologna
Giugno 2024 | DOI: 10.53126/MEBXXVIIGU104
Abstract
This paper takes stock of the current knowledge on the subject of autism spectrum disorders in a fairly detailed way and with relatively simple language. It highlights the main knowledge and concepts shared by the scientific community, which has recently formulated a pathogenic model on an epigenetic basis that justifies the impressive increase in the incidence of the pathology and allows pre- and perinatal prevention to be improved and a multi and interdisciplinary intervention to be hypothesized. Finally, it briefly addresses the therapeutic perspectives.
Riassunto
In questo scritto si fa il punto, in maniera abbastanza dettagliata e con un linguaggio relativamente semplice, sulle attuali conoscenze in tema di disturbi dello spettro autistico, mettendo in luce le principali conoscenze e i concetti condivisi dalla comunità scientifica, che ha recentemente formulato un modello patogenetico su base epigenetica che giustifica l’impressionante aumento dell’incidenza della patologia e permette di migliorare la prevenzione pre- e perinatale e di ipotizzare un intervento multi- e interdisciplinare. L’articolo si conclude con un cenno alle prospettive terapeutiche.
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Per l'acquisto del singolo articolo scrivi a
abbonamenti@medicoebambino.com
(la mail si prepara da sola con gli estremi dell'articolo);
se accedi, la richiesta parte con un click.
Classificazione MeSH
Bibliografia
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). DOI: 10.1176/appi.books.9780890425596.
- Cusick SE, Georgieff MK. The Role of Nutrition in Brain Development: The Golden Opportunity of the "First 1000 Days". J Pediatr. 2016;175:16-21. DOI: 10.1016/j.jpeds.2016.05.013.
- Whitehouse AJO, Varcin KJ, Pillar S, et al. Effect of Preemptive Intervention on Developmental Outcomes Among Infants Showing Early Signs of Autism: A Randomized Clinical Trial of Outcomes to Diagnosis. JAMA Pediatr. 2021;175(11): e213298. DOI: 10.1001/jamapediatrics.2021.3298.
- Constantino JN, Abbacchi AM, Saulnier C, et al. Timing of the Diagnosis of Autism in African American Children. Pediatrics. 2020;146(3): e20193629. DOI: 10.1542/peds.2019-3629.
- Zeidan J, Fombonne E, Scorah J, et al. Global prevalence of autism: A systematic review update. Autism Res. 2022;15(5):778-90. DOI: 10.1002/aur.2696.
- Loomes R, Hull L, Mandy WPL. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(6):466-74. DOI: 10.1016/j.jaac.2017.03.013.
- Werling DM, Geschwind DH. Sex differences in autism spectrum disorders. Curr Opin Neurol. 2013;26(2):146-53. DOI: 10.1097/WCO.0b013e32835ee548.
- Al-Beltagi M. Autism medical comorbidities. World J Clin Pediatr. 2021;10(3):15-28. DOI: 10.5409/wjcp.v10.i3.15.
- Dell'Osso L, Massoni L, Battaglini S, Cremone IM, Carmassi C, Carpita B. Biological correlates of altered circadian rhythms, autonomic functions and sleep problems in autism spectrum disorder. Ann Gen Psychiatry. 2022;21(1):13. DOI: 10.1186/s12991-022-00390-6.
- Madra M, Ringel R, Margolis KG. Gastrointestinal Issues and Autism Spectrum Disorder. Child Adolesc Psychiatr Clin N Am. 2020;29(3):501-13. DOI: 10.1016/j.chc.2020.02.005.
- Lukmanji S, Manji SA, Kadhim S, et al. The co-occurrence of epilepsy and autism: A systematic review. Epilepsy Behav. 2019;98(Pt A):238-48. DOI: 10.1016/j.yebeh.2019.07.037.
- Lamb, G.V., Green, R.J. & Olorunju, S. Tracking epilepsy and autism. Egypt J Neurol Psychiatry Neurosurg 55, 55 (2019). DOI: 10.1186/s41983-019-0103-x.
- Gładysz D, Krzywdzińska A, Hozyasz KK. Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment? Mol Neurobiol. 2018;55(8):6387-435. DOI: 10.1007/s12035-017-0822-x.
- Han VX, Patel S, Jones HF, et al. Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Transl Psychiatry. 2021;11(1):71. DOI: 10.1038/s41398-021-01198-w.
- Yektaş Ç, Alpay M, Tufan AE. Comparison of serum B12, folate and homocysteine concentrations in children with autism spectrum disorder or attention deficit hyperactivity disorder and healthy controls. Neuropsychiatr Dis Treat. 2019;15:2213-19. DOI: 10.2147/NDT.S212361.
- Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290-314. DOI: 10.1038/mp.2010.136.
- Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921-9. DOI: 10.1097/CHI.0b013e318179964f.
- Doherty JL, Owen MJ. Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice. Genome Med. 2014;6(4):29. DOI: 10.1186/gm546.
- Ghezzo A, Visconti P, Abruzzo PM, et al. Oxidative Stress and Erythrocyte Membrane Alterations in Children with Autism: Correlation with Clinical Features. PLoS One. 2013;8(6):e66418. DOI: 10.1371/journal.pone.0066418.
- Abruzzo PM, Ghezzo A, Bolotta A, et al. Perspective Biological Markers for Autism Spectrum Disorders: Advantages of the Use of Receiver Operating Characteristic Curves in Evaluating Marker Sensitivity and Specificity. Dis Markers. 2015;2015:329607. DOI: 10.1155/2015/329607.
- Anwar A, Abruzzo PM, Pasha S, et al. Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis. Mol Autism. 2018;9:3. DOI: 10.1186/s13229-017-0183-3.
- Suzuki K, Matsuzaki H, Iwata K, et al. Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One. 2011;6(5):e20470. DOI: 10.1371/journal.pone.0020470.
- Hu CC, Xu X, Xiong GL, et al. Alterations in plasma cytokine levels in chinese children with autism spectrum disorder. Autism Res. 2018;11(7):989-99. DOI: 10.1002/aur.1940.
- Abruzzo PM, Matté A, Bolotta A, et al. Plasma peroxiredoxin changes and inflammatory cytokines support the involvement of neuroinflammation and oxidative stress in Autism Spectrum Disorder. J Transl Med. 2019;17(1):332. DOI: 10.1186/s12967-019-2076-z.
- Kern JK, Geier DA, Sykes LK, Geier MR. Relevance of Neuroinflammation and Encephalitis in Autism. Front Cell Neurosci. 2016;9:519. DOI: 10.3389/fncel.2015.00519.
- Singh R, Kisku A, Kungumaraj H, et al. Autism Spectrum Disorders: A Recent Update on Targeting Inflammatory Pathways with Natural Anti-Inflammatory Agents. Biomedicines. 2023;11(1):115. DOI: 10.3390/biomedicines11010115.
- Morais LH, Schreiber HL 4th, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021;19(4):241-55. DOI: 10.1038/s41579-020-00460-0.
- Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychi-atry. 2019;9(1):233. DOI: 10.1038/s41398-019-0570-y.
- Panisi C, Guerini FR, Abruzzo PM, et al. Autism Spectrum Disorder from the Womb to Adulthood: Suggestions for a Paradigm Shift. J Pers Med. 2021;11(2):70. DOI: 10.3390/jpm11020070.
- Imamura A, Morimoto Y, Ono S, et al. Genetic and environmental factors of schizophrenia and autism spectrum disorder: insights from twin studies. J Neural Transm (Vienna). 2020;127(11):1501-15. DOI: 10.1007/s00702-020-02188-w.
- Leblond CS, Le TL, Malesys S, et al. Operative list of genes associated with autism and neurodevelopmental disorders based on database review. Mol Cell Neurosci. 2021;113:103623. DOI: 10.1016/j.mcn.2021.103623.
- Rodin RE, Dou Y, Kwon M, et al. The landscape of somatic mutation in cerebral cortex of autistic and neurotypical individuals revealed by ultra-deep whole-genome sequencing. Nat Neurosci. 2021;24(2):176-85. DOI: 10.1038/s41593-020-00765-6.
- Panisi C, Burgio E. Dalla genetica all’epigenetica: cosa cambia nella pratica clinica dell’ASD. AreaPed 2021;22(3):126-33. DOI: 10.1725/3671.36572.
- Bernhardt ES, Rosi EJ, Gessner MO. Synthetic chemicals as agents of global change. Frontiers in Ecology and the Environment 2017;15(2):84-90.
- Ramírez V, González-Palacios P, Baca MA, et al. Effect of exposure to endocrine disrupting chemicals in obesity and neurodevelopment: The genetic and microbiota link. Sci Total Environ. 2022;852:158219. DOI: 10.1016/j.scitotenv.2022.158219.
- Doi M, Usui N, Shimada S. Prenatal Environment and Neurodevelopmental Disorders. Front Endo-crinol (Lausanne). 2022;13:860110. DOI: 10.3389/fendo.2022.860110.
- Katz J, Reichenberg A, Kolevzon A. Prenatal and perinatal metabolic risk factors for autism: a review and integration of findings from population-based studies. Curr Opin Psychiatry. 2021;34(2):94-104. DOI: 10.1097/YCO.0000000000000673.
- Tiffon C. The Impact of Nutrition and Environmental Epigenetics on Human Health and Disease. Int J Mol Sci. 2018;19(11):3425. DOI: 10.3390/ijms19113425.
- Kirtana A, Seetharaman B. Comprehending the Role of Endocrine Disruptors in Inducing Epigenetic Toxicity. Endocr Metab Immune Disord Drug Targets. 2022;22(11):1059-72. DOI: 10.2174/1871530322666220411082656.
- Cheng W, Rolls ET, Gu H, Zhang J, Feng J. Autism: reduced connectivity between cortical areas involved in face expression, theory of mind, and the sense of self. Brain. 2015;138(Pt 5):1382-93. DOI: 10.1093/brain/awv051.
- Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021;12(1):6. DOI: 10.1186/s13229-021-00420-2.
- Pretzsch CM, Floris DL, Voinescu B, et al. Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. Mol Autism. 2021;12(1):49. DOI: 10.1186/s13229-021-00454-6.
- Desousa A. An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder. Indian J Psychol Med. 2010;32(1):17-21. DOI: 10.4103/0253-7176.70522.
- Geschwind DH. Advances in autism. Annu Rev Med. 2009;60:367-80. DOI: 10.1146/annurev.med.60.053107.121225.
- Zinovkin RA, Zamyatnin AA. Mitochondria-Targeted Drugs. Curr Mol Pharmacol. 2019;12(3):202-14. DOI: 10.2174/1874467212666181127151059.
- Posar A, Visconti P. Complementary and Alternative Medicine in Autism: The Question of Omega-3. Pediatr Ann. 2016;45(3):e103-7. DOI: 10.3928/00904481-20160129-01.
- Zimmerman AW, Singh K, Connors SL, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Mol Autism. 2021;12(1):38. DOI: 10.1186/s13229-021-00447-5. Erratum in: Mol Autism. 2021;12(1):44.
- Cordaro M, Cuzzocrea S, Crupi R. An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events. Antioxidants (Basel). 2020;9(3):216. DOI: 10.3390/antiox9030216.
- Agus A, Planchais J, Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018;23(6):716-24. DOI: 10.1016/j.chom.2018.05.003.
- Prosperi M, Santocchi E, Guiducci L, et al. Interventions on Microbiota: Where Do We Stand on a Gut-Brain Link in Autism? A Systematic Review. Nutrients. 2022;14(3):462. DOI: 10.3390/nu14030462.